Enhancement of gametocytogenesis in Plasmodium falciparum by genetic engineering for improved PfSPZ Vaccine Manufacture

通过基因工程增强恶性疟原虫配子细胞发生以改进 PfSPZ 疫苗生产

基本信息

  • 批准号:
    10239239
  • 负责人:
  • 金额:
    $ 30万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2020
  • 资助国家:
    美国
  • 起止时间:
    2020-08-17 至 2023-07-31
  • 项目状态:
    已结题

项目摘要

The WHO estimates that in 2018, malaria caused ~228M clinical episodes and ~405,000 deaths worldwide. Despite an annual investment of >$3 billion for control measures, 2018 was the 3rd consecutive year in which there was no decrease in malaria cases, indicating a saturation of capacity to implement further impact with currently available strategies. There is an urgent unmet medical need for a highly efficacious malaria vaccine that prevents infection and disease. Sanaria’s 1st generation vaccine based on radiation-attenuated, aseptic, purified, cryopreserved Plasmodium falciparum (Pf) sporozoites (SPZ) PfSPZ Vaccine has been assessed in 19 clinical trials in 6 countries in Africa, 2 countries in Europe, and the US, and received Fast Track designation from the FDA. Clinical trials with Phase 3 compliant vaccine will begin in mid 2020, and licensure (marketing authorization) in the US (FDA) and in Europe (EMA) is planned for 2022. PfSPZ Vaccine is targeted to prevent malaria in travelers to and residents of Africa, and for immunizing the entire community to halt transmission and eliminate malaria from geographically focused areas of Africa. During the next 5-10 years, we aim to significantly increase potency and decrease cost of goods (COGs) of PfSPZ-based vaccines so they can be optimally used to prevent Pf malaria. One of our strategies to improve the breadth of protection in our vaccines is to include additional strains of Pf from geographically diverse regions such as Pf7G8 (Brazil) and PfNF135.C10 (Cambodia). Other than PfNF54 (West Africa strain), all other Pf strains assessed in humans are poor gametocyte producers. An approach to improving the efficiency of large-scale production of PfSPZs from different geographic regions and decreasing COGs would be generating increased numbers of fertile gametocytes per unit of culture for production of PfSPZ in mosquitoes. In nature, gametocytogenesis occurs only in a small subset of blood stage parasites due to epigenetic suppression of gametocytogenesis-related genes. Control of gametocyte commitment would provide a powerful tool for improving production of PfSPZ. A key molecule in this process is the master switch transcription factor, PfAP2-G, the expression of which correlates directly with the percent of gametocytes produced by a given Pf strain. Deletion of this gene completely abolishes gametocyte production. We propose to increase the gametocyte production capacity of Sanaria’s vaccine strains and decrease PfSPZ manufacturing COGs by over-expressing this gene by using CRISPR-Cas9 gene editing to modify the pairing elements (PE) in the 3’-UTR of pfap2-g. As an alternative, we will also relieve epigenetic silencing of PfAP2-G by replacing its promoter with the constitutive calmodulin promoter in a conditionally regulatable gametocyte induction (on/off) system we have developed. We will generate enhanced gametocyte-producing lines of Pf from different geographic regions, compare and evaluate clones with enhanced gametocytogenesis and select those with optimal in vitro growth that maintain high prevalence and intensities of infectious PfSPZs in aseptic mosquitoes.
世卫组织估计,2018年,疟疾在全球造成约2.28亿例临床发作和约40.5万例死亡。 尽管每年投资超过30亿美元用于控制措施,但2018年是连续第三年, 疟疾病例没有减少,表明实施进一步影响的能力已经饱和, 现有的战略。对高效疟疾疫苗的迫切医疗需求尚未得到满足 防止感染和疾病。Sanaria的第一代疫苗基于辐射减毒,无菌, 纯化、冷冻保存的恶性疟原虫(Pf)子孢子(SPZ)PfSPZ疫苗已在 在非洲6个国家、欧洲2个国家和美国进行了19项临床试验,并获得了快速通道 FDA的认定。符合3期标准的疫苗的临床试验将于2020年年中开始, (上市许可)计划于2022年在美国(FDA)和欧洲(EMA)进行。PfSPZ疫苗是靶向的 在非洲的旅行者和居民中预防疟疾,并为整个社区接种疫苗, 在非洲的重点地区消灭疟疾。在未来5-10年,我们 旨在显著提高PfSPZ疫苗的效力并降低其商品成本(COG), 可以最佳地用于预防Pf疟疾。我们的战略之一是提高我们 疫苗将包括来自地理上不同地区的其他Pf菌株,如Pf 7 G8(巴西)和 PfNF135.C10(柬埔寨)。除PfNF 54(西非毒株)外,在人类中评估的所有其他Pf毒株均为 可怜的配子体生产者。提高大规模生产PfSPZ效率的途径 不同的地理区域和减少的COG将产生更多的肥沃的土壤, 每单位培养物中的配子体用于在蚊子中产生PfSPZ。在自然界中, 仅在一小部分血液期寄生虫中,由于配子体发生相关的表观遗传抑制, 基因.控制配子体的承诺将提供一个强大的工具,提高生产PfSPZ。一 这个过程中的关键分子是主开关转录因子PfAP 2-G,其表达 与给定Pf菌株产生的配子母细胞的百分比直接相关。该基因的缺失 完全消除配子体的产生。我们建议增加配子体的生产能力, Sanaria的疫苗株,并通过使用过量表达该基因来减少PfSPZ生产COG。 CRISPR-Cas9基因编辑以修饰pfap 2-g的3 '-UTR中的配对元件(PE)。作为替代方案,我们 也将通过用组成型钙调蛋白替换PfAP 2-G的启动子来减轻PfAP 2-G的表观遗传沉默 启动子在条件调控配子体诱导(开/关)系统,我们已经开发。我们将 产生来自不同地理区域的Pf的增强的配子体产生系,比较和评估 具有增强的配子体发生的克隆,并选择那些具有最佳体外生长的克隆, 无菌蚊中感染性PfSPZ的患病率和强度。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

STEPHEN Lev HOFFMAN其他文献

STEPHEN Lev HOFFMAN的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('STEPHEN Lev HOFFMAN', 18)}}的其他基金

Modularizing manufacture of PfSPZ vaccines: ookinete production for PfSPZ manufacture in mosquitoes and in vitro
PfSPZ 疫苗的模块化生产:在蚊子和体外生产 PfSPZ 的动合生产
  • 批准号:
    10761373
  • 财政年份:
    2023
  • 资助金额:
    $ 30万
  • 项目类别:
Progressing PfSPZ vaccines for malaria to licensure and commercialization
推进 PfSPZ 疟疾疫苗的许可和商业化
  • 批准号:
    10602357
  • 财政年份:
    2023
  • 资助金额:
    $ 30万
  • 项目类别:
PfSPZ Vaccine for Prevention of Plasmodium falciparum malaria
用于预防恶性疟原虫疟疾的 PfSPZ 疫苗
  • 批准号:
    10406059
  • 财政年份:
    2022
  • 资助金额:
    $ 30万
  • 项目类别:
Attenuation of Liquid Formulation for PfSPZ Vaccine by X-Ray
X 射线法测定 PfSPZ 疫苗液体制剂的减毒效果
  • 批准号:
    10156019
  • 财政年份:
    2021
  • 资助金额:
    $ 30万
  • 项目类别:
Attenuation of Liquid Formulation for PfSPZ Vaccine by X-Ray
X 射线法测定 PfSPZ 疫苗液体制剂的减毒效果
  • 批准号:
    10391482
  • 财政年份:
    2021
  • 资助金额:
    $ 30万
  • 项目类别:
Development of Non-Human Primate Models to Assess Immunological Mechanisms and Antigenic Targets of Protective Sporozoite (SPZ) Vaccines and Establish Superior Efficacy of Next Generation SPZ vaccines
开发非人灵长类动物模型来评估保护性子孢子 (SPZ) 疫苗的免疫机制和抗原靶点并确定下一代 SPZ 疫苗的卓越功效
  • 批准号:
    10381696
  • 财政年份:
    2021
  • 资助金额:
    $ 30万
  • 项目类别:
Development of Non-Human Primate Models to Assess Immunological Mechanisms and Antigenic Targets of Protective Sporozoite (SPZ) Vaccines and Establish Superior Efficacy of Next Generation SPZ vaccines
开发非人灵长类动物模型来评估保护性子孢子 (SPZ) 疫苗的免疫机制和抗原靶点并确定下一代 SPZ 疫苗的卓越功效
  • 批准号:
    10598147
  • 财政年份:
    2021
  • 资助金额:
    $ 30万
  • 项目类别:
Enhancement of gametocytogenesis in Plasmodium falciparum by genetic engineering for improved PfSPZ Vaccine Manufacture
通过基因工程增强恶性疟原虫配子细胞发生以改进 PfSPZ 疫苗生产
  • 批准号:
    10082070
  • 财政年份:
    2020
  • 资助金额:
    $ 30万
  • 项目类别:
Manufacture of aseptic, purified, cryopreserved Plasmodium vivax sporozoites (PvSPZ Challenge) for controlled human malaria infection (CHMI)
生产无菌、纯化、冷冻保存的间日疟原虫子孢子(PvSPZ Challenge)用于控制人类疟疾感染(CHMI)
  • 批准号:
    9265783
  • 财政年份:
    2016
  • 资助金额:
    $ 30万
  • 项目类别:
Manufacture of aseptic, purified, cryopreserved Plasmodium vivax sporozoites
无菌、纯化、冷冻保存的间日疟原虫子孢子的制造
  • 批准号:
    10011236
  • 财政年份:
    2016
  • 资助金额:
    $ 30万
  • 项目类别:

相似海外基金

ESE: Collaborative Research: Climate Change and Variability and Armed Conflicts in Africa South of the Sahara
ESE:合作研究:撒哈拉以南非洲的气候变化和变异性以及武装冲突
  • 批准号:
    0964515
  • 财政年份:
    2010
  • 资助金额:
    $ 30万
  • 项目类别:
    Standard Grant
Network Dynamics, Sexual Behaviour, and HIV Among University Students in Africa South of the Sahara
撒哈拉以南非洲大学生的网络动态、性行为和艾滋病毒
  • 批准号:
    178094
  • 财政年份:
    2008
  • 资助金额:
    $ 30万
  • 项目类别:
    Studentship Programs
Synopsis of Ichneumoniae of Africa, South of the Sahara
撒哈拉以南非洲的姬蜂病简介
  • 批准号:
    66B2956
  • 财政年份:
    1966
  • 资助金额:
    $ 30万
  • 项目类别:
To Attend Synopsis of Ichneumoninae of Africa, South of the Sahara
参加撒哈拉以南非洲的姬蜂亚科概要
  • 批准号:
    65B2956
  • 财政年份:
    1965
  • 资助金额:
    $ 30万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了